🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to health experts.

An International Challenge

The sexually transmitted infection are on the rise worldwide, with figures suggesting over 82 million new cases each year. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs currently available.”

Health officials are deeply concerned about the surge in drug-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

Zoliflodacin, alternatively called a brand name, was authorized by the US FDA in recent days for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts anticipate that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in the same week. This drug, which is employed against urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization marks a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

According to findings detailed in a major medical journal, the new drug eradicated over nine in ten of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The trial involved over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the ability to license and sell the drug in a wide range of developing nations.

Medical professionals treating patients have expressed positive views. Having a single-dose, oral treatment of this kind is seen as a "game-changer" for gonorrhoea control. This is deemed vital to alleviate the strain of the illness for people and to prevent the spread of extremely resistant gonorrhoea worldwide.